N1-Methyl-4-nitrobenzene-1,2-diamine

We are N1-Methyl-4-nitrobenzene-1,2-diamine CAS:41939-61-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  N1-Methyl-4-nitrobenzene-1,2-diamine
CAS.NO:41939-61-1
Synonyms:
1-N-methyl-4-nitrobenzene-1,2-diamine
N1-Methyl-4-nitro-1,2-phenylenediamine
2-Amino-1-methylamino-4-nitrobenzene
1,2-Diamino-N1-methyl-4-nitrobenzene

Molecular Formula:C7H9N3O2
Molecular Weight:167.16500

Physical and Chemical Properties:
Density: 1.358g / cm3
Boiling point: 366.8ºC at 760 mmHg
Melting point: 174-176ºC
Flash point: 175.6ºC
Refractive index: 1.682

Specification:
Appearance:  red powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Refrigerator.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Bendamustine hydrochloride CAS:3543-75-7
Intermediates of Bendamustine CAS:16506-27-7

N1-Methyl-4-nitrobenzene-1,2-diamine


Related News: With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.azetidin-3-ona, hidrocloruro CAS:17557-84-5 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.N-benzyl-2-(2-methoxyphenoxy)ethanamine “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.methyl 2-bromo-3-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]propanoate CAS:105355-25-7 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride View Details
N5-ethyl-L-glutamine View Details
acetone oxime View Details
4-Methoxy-2-Methyldiphenylamine manufacturer Calcium iodate manufacturer Fmoc-D-Tyr(Et)-OH manufacturer 3-pyridinecarbonitrile manufacturer 2-Bromo-4′-nitroacetophenone manufacturer